Harbor Advisors LLC Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA)

Harbor Advisors LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, Holdings Channel.com reports. The fund acquired 3,000 shares of the company’s stock, valued at approximately $298,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. First Pacific Financial bought a new stake in Moderna in the 3rd quarter valued at approximately $27,000. Arlington Trust Co LLC lifted its stake in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its stake in Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after acquiring an additional 180 shares in the last quarter. Archer Investment Corp lifted its stake in Moderna by 71.2% in the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after acquiring an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its stake in Moderna by 44.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after acquiring an additional 175 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the transaction, the director now directly owns 2,101,931 shares in the company, valued at $229,236,594.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock valued at $11,533,976 in the last ninety days. 15.20% of the stock is currently owned by corporate insiders.

Moderna Stock Performance

NASDAQ MRNA traded up $3.43 on Tuesday, reaching $107.89. The stock had a trading volume of 2,392,140 shares, compared to its average volume of 4,125,648. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The firm has a fifty day moving average of $100.94 and a two-hundred day moving average of $93.51. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79. The company has a market cap of $41.31 billion, a P/E ratio of -8.71 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same period in the prior year, the firm posted $3.61 EPS. The company’s revenue for the quarter was down 44.9% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. HSBC restated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $126.49.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.